Search by Symbol
View Universe
FINRA:SIPC

Taglich Brothers RSS







Disclaimer

 
Taglich's Company Profile for:

www.neogenomics.org

Receive email alerts for this company

NeoGenomics, Inc.

Symbol: NGNM
Analyst:  
Juan Noble
Taglich Rating:
   Speculative Buy
Price Target:   $2.30
Time Horizon:   12 Months
Rating Established:   August 4, 2008
   
Price When Established:   $0.95
Most Recent Report: November 11, 2008
    Price When Issued: $0.70

Most Recent Update

Updated Earnings Note (Dated November 6, 2008)

What's New
New information will be posted soon...
Company Description
NeoGenomics, Inc. (NGNM.OB) operates high complexity clinical laboratories performing specialized, high-value genetic tests used in the diagnosis and prognosis of cancer. The company, which began operations in 2002, is headquartered in Fort Myers, FL, and also operates laboratories in Nashville, TN and Irvine, CA. The company’s facilities are licensed under all relevant Federal and state laws, and its services qualify for reimbursement under major government insurance programs, principally Medicare and Medicaid.

Genetic testing, distinct from the larger clinical laboratory and anatomic testing segments of the market, analyzes chromosomes, genes and DNA, seeking abnormalities that confirm cancer diagnoses. Genetic testing, the fastest growing segment of the clinical testing market, is characterized by high-cost (and high margin) tests. The company also operates a contract research organization. The company’s facilities are licensed under all relevant Federal and state laws, and its services qualify for reimbursement under major government insurance programs, principally Medicare and Medicaid.
Taglich Research Reports
Initial Research Report (Dated August 4, 2008)

All Research Reports are in Adobe Acrobat format.
(for the latest Adobe Acrobat reader click here)

* The information and statistical data contained herein have been obtained from sources, which we believe to be reliable but in no way are warranted by us as to accuracy or completeness. We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statements are the opinion of Taglich Brothers, Inc. and are not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in the reports are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from the Director of Research. As of the date of this report, no officers or employees of Taglich Brothers, Inc. owned any of the company’s shares. All research issued by Taglich Brothers, Inc. is based on public information. Taglich Brothers, Inc. does not currently have an Investment Banking relationship with the company mentioned and was not a manager or co-manager of any offering for the company within the last three years. All research issued by Taglich Brothers, Inc. is based on public information. In June, 2008, the company paid a monetary fee of US$6,000, representing payment for the first three of 12 months, for the creation and dissemination of research reports. From October, 2008 through June, 2009, the company will pay a monthly monetary fee of US$2,000, for a total one-year fee of US$24,000 for the creation and dissemination of research reports. For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.

Send this Page to a friend

To send this page to a friend, just fill out the form below and press the "send it" button!

Your Name
Your E-mail
Your Friend's Name
Your Friend's E-mail
Market Data
Bloomberg
Hoover's Capsule
SEC Filings
Yahoo Finance
Taglich Covered Companies
AeroCentury Corp.
Anglo Swiss Resources, Inc.
BioForce Nanosci. Holdings, Inc.
Carbiz, Inc.
Cardium Therapeutics, Inc.
Command Security Corp.
CTI Industries Corp
Derma Sciences, Inc.
DRI Corporation
EnerLume Energy Mgt. Corp.
GammaCan International, Inc.
Hartmarx Corporation
Hyperdynamics Corporation
INX, Inc.
Life Partners Holdings, Inc.
Lifeway Foods, Inc.
Littlefield Corporation
Micro Imaging Tech, Inc.
NeoGenomics, Inc.
Orchids Paper Products
Park City Group, Inc.
Pressure BioSciences, Inc.
Radiant Logistics, Inc.
Reed's Inc.
Salon Media Group, Inc.
Simulations Plus, Inc.
SMF Energy Corporation
TranSwitch Corporation
UFP Technologies, Inc.
US 1 Industries, Inc.
Wave Systems Corp.
Williams Controls, Inc.

This site is best viewed at 800x600 with: Internet Explorer Click Here for more information.
Ticker powered by TickerTech.com. Copyright © 2000 Ticker Technologies Inc., All Rights Reserved. Quote data at least 20 minutes delayed. Please read other important disclaimer information.